Abstract:Background Hereditary spastic paraplegias (HSPs) are a group of genetically heterogeneous neurodegenerative disorders characterized primarily by progressive spasticity and weakness in the lower limbs. Our objective was to determine the clinical and molecular characteristics of patients with genetically confirmed childhood-onset HSPs and to expand the genetic spectrum for some rare subtypes of HSP. Methods We reviewed the charts of subjects with genetically confirmed childhood-onset HSP. The age at the disease onset was defined as the point at which the delayed motor milestones were observed. Delayed motor milestones were defined as being unable to hold the head up by four months, sitting unassisted by nine months, and walking independently by 17 months. If there were no delayed motor milestones, age at disease onset was determined by leg stiffness, frequent falls, or unsteady gait. Genetic testing was performed based on delayed motor milestones, progressive leg spasticity, and gait difficulty. The variant classification was determined based on the American College of Medical Genetics (ACMG) standard guidelines for variant interpretation. Variants of uncertain significance (VUS) were considered disease-associated when clinical findings were consistent with the previously described disease phenotypes for pathogenic variants. In addition, in the absence of another pathogenic, likely pathogenic, or VUS variant that could explain the phenotype of our cases, we concluded that the disease is associated with VUS in the HSP-causing gene. Segregation analysis was also performed on the parents of some patients in order to demonstrate the inheritance model. Results There was a total of 18 patients from 17 families. The median age of symptom onset was 18 months (2 to 84 months). The mean delay between symptom onset and genetic diagnosis was 5.8 years (5 months to 17 years). All patients had gait difficulty caused by progressive leg spasticity and weakness. Independent walking was not achieved at 17 months for 67% of patients (n = 12). In our cohort, there were two subjects each with SPG11, SPG46 and SPG 50 followed by single subject each with SPG3A, SPG4, SPG7, SPG8, SPG30, SPG35, SPG43, SPG44, SPG57, SPG62, IAHSP, and SPPRS. Eight novel variants in nine patients were described. Two affected siblings had a novel variant in the GBA2 gene (SPG46), and one subject each had a novel variant in WASHC5 (SPG8), SPG11 (SPG11), KIF1A (SPG30), GJC2 (SPG44), ERLIN1 (SPG62), ALS2 (IAHSP), and HACE1 (SPPRS). Among the novel variants, the variant in the SPG11 was pathogenic, and the variants in the KIF1A , GJC2 , and HACE1 were likely pathogenic. The variants in the GBA2, ALS2, ERLIN1 , and WASHC5 were classified as VUS. Conclusion There was a significant delay between symptom onset and genetic diagnosis of HSP. An early diagnosis may be possible by examining patients with delayed motor milestones, progressive spasticity, gait difficulties, and neuromuscular weakness in the context of HSP. Eight novel variants in nine patients were described, clinically similar to the previously described disease phenotype associated with pathogenic variants. This study contributes to expanding the genetic spectrum of some rare subtypes of HSP.

SPG6 (NIPA1 variant): A report of a case with early-onset complex hereditary spastic paraplegia and brief literature review

Expansion of the Phenotypic Spectrum of SPG6 Caused by Mutation in NIPA1.

[The Clinical Characteristics of a Pedigree with Incompletely Penetrated Autosomal Dominant Hereditary Spastic Paraplegia and Its Exclusion Analysis of Genetic Loci].

SPTAN1 Variants Likely Cause Autosomal Recessive Complicated Hereditary Spastic Paraplegia

Receptor Expression-Enhancing Protein 1 Gene (SPG31) Mutations Are Rare in Chinese Han Patients with Hereditary Spastic Paraplegia.

Exon 8-17 Deletions of Spast in A Chinese Family with Hereditary Spastic Paraplegia: A Case Report and Literature Review

Clinical and genetic study of SPG6 mutation in a Chinese family with hereditary spastic paraplegia

Hereditary spastic paraparesis type 46 (SPG46): new GBA2 variants in a large Italian case series and review of the literature

Mutation and Clinical Characteristics of Autosomal-Dominant Hereditary Spastic Paraplegias in China

Early Diagnosis of AP5Z1/SPG48 Spastic Paraplegia: Case Report and Review of the Literature

Novel Mutations in the SPAST Gene Cause Hereditary Spastic Paraplegia.

Early-Onset and Severe Complex Hereditary Spastic Paraplegia Caused by De Novo Variants in SPAST

Genetic Analysis of SPG4 and SPG3A Genes in a Cohort of Chinese Patients with Hereditary Spastic Paraplegia.

Distinct novel mutations affecting the same base in the NIPA1 gene cause autosomal dominant hereditary spastic paraplegia in two Chinese families.

Patients with complex and very-early-onset ATL1-related spastic paraplegia offer insights on genotype/phenotype correlations and support for autosomal recessive forms of SPG3A

Genetic, clinical and neuroimaging profiles of sporadic and autosomal recessive hereditary spastic paraplegia cases in Chinese

Novel variants in AP4B1 cause spastic tetraplegia, moderate psychomotor development delay and febrile seizures in a Chinese patient: a case report

Clinical and genetic characteristics in a Chinese cohort of complex spastic paraplegia type 4

New genetic causes for complex hereditary spastic paraplegia

A retrospective review of 18 patients with childhood-onset hereditary spastic paraplegia, nine with novel variants

Spastic Paraplegia Type 76 Due to Novel CAPN1 Mutations: Three Case Reports with Literature Review